Canopy Growth: Analysts Expect Q2 Revenues Of $142.5 Million

Canopy Growth Corp (TSX: WEED) (NASDAQ: CGC) announced that they will be reporting their fiscal second quarter financials before market open on November 5th.

Analysts have a consensus C$26.94 12-month price target on the company, via a total of 14 analysts, with 2 analysts having buy ratings, 11 have holds and 1 analyst has a strong sell rating on the stock. Nine analysts have a hold rating and two analysts have a strong sell rating. The street high comes from MKM Partners with a C$51 price target, and the lowest target comes from Stifel-GMP with a C$15 price target.

13 analysts have revenue estimates for the second quarter. The mean between all 13 is C$142.49 million; this number has been revised downwards from C$191.25 million at the start May. The street high is C$173.10 million while the lowest sits at C$130 million.

Six analysts have estimates for what this quarter’s gross profit margin will be. They expect the profit margin to come in at 21.42%, with this number being revised downwards from 34.30% at the start of May. Street high goes to CIBC Capital Markets with a 26.50% estimate and the lowest sits at 16%.

Onto EBITDA estimates, there are currently 12 analysts who have second quarter EBITDA estimates. The mean is currently (C$52.35) million, with this number being lower at the start of May. Street high goes to Benchmark with a (C$36) million EBITDA estimate and the lowest being a (C$67.3) million estimate.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Building the $500M-a-Year Gold Mine | Victor Cantore – Amex Gold Mining

Building the Next 500,000-Ounce Gold Producer | Stephen Soock – Heliostar Metals

This Gold Explorer Is Making Its Biggest Bet | Brian Miller – Astra Exploration

Recommended

This Gold Discovery Just Keeps Getting Bigger | Roger Rosmus – Goliath Resources

Cardiol Expands MAVERIC Trial to Up to 150 Patients After Reaching Enrollment Target Early

Related News

Raymond James: Village Farms’ Revenue Miss Is An “Artifact of Consolidation”

Yesterday, Village Farms (TSX: VFF) (NASDAQ: VFF) reported fourth quarter and year-end earnings. The company...

Wednesday, March 17, 2021, 04:11:00 PM

Goldman Sachs Forecasts Bullish Oil Market in 2021

Armed with the optimism of a successful COVID-19 vaccine by next year, Goldman Sachs has...

Wednesday, September 2, 2020, 03:01:00 PM

Columbia Care Sees Consensus Price Target Rise To $14.70

On August 12, Columbia Care Inc. (CSE: CCHW) reported its second-quarter financial results, wherein the...

Wednesday, August 18, 2021, 10:09:00 AM

Beyond Meat: Analysts Anticipate $113.33 Million In Q1 Revenues

Beyond Meat (NASDAQ: BYND) will be reporting its first quarter financial results today after market...

Thursday, May 6, 2021, 02:34:00 PM

BioSteel Owes Millions To NHL, Professional Sports Teams: Bankruptcy Filing

Canopy Growth’s (TSX: WEED) BioSteel Sports Nutrition Inc. finds itself in a significant financial bind,...

Wednesday, September 20, 2023, 11:02:00 AM